Circio’s CEO on the new strategy
Circio, formerly known as Targovax, is a Norwegian immunotherapy company within RNA-based therapeutics. The company is focusing on circular RNA, which holds several advantages over mRNA, according to CEO Erik Digman Wiklund. The potential of circular RNA has been acknowledged by the industry, as the area is attracting a lot of interest and investments.
Watch the interview with Circio’s CEO Erik Digman Wiklund in the link below.
Learn more about Circio on the company’s website.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
